{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:48:40Z","timestamp":1793774920412,"version":"4.6.1"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    Cerebrotendinous Xanthomatosis represents a rare and underdiagnosed inherited neurometabolic disorder due to homozygous or compound heterozygous variants involving the\n                    <jats:italic>CYP27A1<\/jats:italic>\n                    gene. This bile acid metabolism disorder represents a key potentially treatable neurogenetic condition due to the wide spectrum of neurological presentations in which it most commonly occurs. Cerebellar ataxia, peripheral neuropathy, spastic paraparesis, epilepsy, parkinsonism, cognitive decline, intellectual disability, and neuropsychiatric disturbances represent some of the most common neurological signs observed in this condition. Despite representing key features to increase diagnostic index suspicion, multisystemic involvement does not represent an obligatory feature and can also be under evaluated during diagnostic work-up. Chenodeoxycholic acid represents a well-known successful therapy for this inherited metabolic disease, however its unavailability in several contexts, high costs and common use in patients at late stages of disease course limit more favorable neurological outcomes for most individuals. This review article aims to discuss and highlight the most recent and updated knowledge regarding clinical, pathophysiological, neuroimaging, genetic and therapeutic aspects related to Cerebrotendinous Xanthomatosis.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2022.1049850","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T01:37:15Z","timestamp":1671759435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Cerebrotendinous Xanthomatosis: A practice review of pathophysiology, diagnosis, and treatment"],"prefix":"10.3389","volume":"13","author":[{"given":"Paulo Ribeiro","family":"N\u00f3brega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson Moura","family":"Bernardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Mariano","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Costa","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Augusto Batista S\u00e1","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor Carneiro de Vasconcelos","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Fussiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina de Figueiredo","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Aguiar","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Lu\u00edz Santos","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladimir Bocca Vieira de Rezende","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Alex Morales","family":"Saute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Victor Sgobbi de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Braga-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.5551\/jat.RV17055","article-title":"Cerebrotendinous Xanthomatosis: molecular pathogenesis, clinical spectrum, diagnosis, and disease-modifying treatments","volume":"28","author":"Koyama","year":"2021","journal-title":"J Atheroscler Thromb."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40673-021-00128-2","article-title":"Cerebrotendinous Xanthomatosis: diversity of presentation and refining treatment with chenodeoxycholic acid","volume":"8","author":"Islam","year":"2021","journal-title":"Cerebellum Ataxias."},{"key":"B3","first-page":"69","article-title":"Une deuxieme observation de cholesterinose tendineuse avec symptomes cerebraux","volume":"42","author":"Van Bogaert","year":"1937","journal-title":"Ann Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ajmg.1320100209","article-title":"Genetics of Cerebrotendinous Xanthomatosis (CTX): an autosomal recessive trait with high gene frequency in sephardim of Moroccan origin","volume":"10","author":"Berginer","year":"1981","journal-title":"Am J Med Genet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ymgme.2015.10.010","article-title":"Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes","volume":"116","author":"Appadurai","year":"2015","journal-title":"Mol Genet Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13023-021-01980-5","article-title":"Expert opinion on diagnosing, treating and managing patients with Cerebrotendinous Xanthomatosis (CTX): a modified Delphi study","volume":"16","author":"Stelten","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10545-017-0093-8","article-title":"Epidemiology, diagnosis, and treatment of Cerebrotendinous Xanthomatosis (CTX)","volume":"40","author":"Salen","year":"2017","journal-title":"J Inherit Metab Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1074\/jbc.M116.774760","article-title":"Cytochrome P450 27A1 deficiency and regional differences in brain sterol metabolism cause preferential cholestanol accumulation in the cerebellum","volume":"292","author":"Mast","year":"2017","journal-title":"J Biol Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13023-014-0179-4","article-title":"Cerebrotendinous Xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management","volume":"9","author":"Nie","year":"2014","journal-title":"Orphanet J Rare Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12017-020-08625-z","article-title":"Bile acids: a communication channel in the gut-brain axis","volume":"23","author":"Monteiro-Cardoso","year":"2021","journal-title":"Neuromolecular Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10545-015-9873-1","article-title":"Evaluation of cholesterol metabolism in Cerebrotendinous Xanthomatosis","volume":"39","author":"Mignarri","year":"2016","journal-title":"J Inherit Metab Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10545-018-0152-9","article-title":"Natural history of neurological abnormalities in Cerebrotendinous Xanthomatosis","volume":"41","author":"Wong","year":"2018","journal-title":"J Inherit Metab Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"20190047","DOI":"10.1259\/bjrcr.20190047","article-title":"Multi-imaging study in a patient with Cerebrotendinous Xanthomatosis: radiology, clinic and pathology correlation of a rare condition","volume":"6","author":"Orabona","year":"2020","journal-title":"BJR Case Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1179\/135100007X200173","article-title":"Cerebrotendinous Xanthomatosis: case report with evidence of oxidative stress","volume":"12","author":"Gonzalez-Cuyar","year":"2007","journal-title":"Redox Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1212\/WNL.0000000000006731","article-title":"Long-term treatment effect in Cerebrotendinous Xanthomatosis depends on age at treatment start","volume":"92","author":"Stelten","year":"2019","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1176\/ajp.145.3.354","article-title":"Psychiatric disorders in patients with Cerebrotendinous Xanthomatosis","volume":"145","author":"Berginer","year":"1988","journal-title":"Am J Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s10038-017-0389-4","article-title":"Nationwide survey on cerebrotendinous xanthomatosis in Japan","volume":"63","author":"Sekijima","year":"2018","journal-title":"J Hum Genet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.12998\/wjcc.v8.i21.5446","article-title":"Chinese patient with Cerebrotendinous Xanthomatosis confirmed by genetic testing: a case report and literature review","volume":"8","author":"Cao","year":"2020","journal-title":"World J Clin Cases."},{"key":"B19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/MPG.0000000000001730","article-title":"Severe neonatal cholestasis in Cerebrotendinous Xanthomatosis: genetics, immunostaining, mass spectrometry","volume":"65","author":"Gong","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10072-006-0618-7","article-title":"Clinical and molecular diagnosis of Cerebrotendinous Xanthomatosis with a review of the mutations in the CYP27A1 gene","volume":"27","author":"Gallus","year":"2006","journal-title":"Neurol Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-319-33943-6_10","article-title":"Tendons involvement in congenital metabolic disorders","volume":"920","author":"Abate","year":"2016","journal-title":"Adv Exp Med Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.parkreldis.2018.07.006","article-title":"Movement disorders in Cerebrotendinous Xanthomatosis","volume":"58","author":"Stelten","year":"2019","journal-title":"Parkinsonism Relat Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.parkreldis.2020.09.002","article-title":"Movement disorders in the early-diagnosed Cerebrotendinous Xanthomatosis: an electrophysiological study","volume":"80","author":"Aktuglu Zeybek","year":"2020","journal-title":"Parkinsonism Relat Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/mus.21905","article-title":"Neurophysiological study in Cerebrotendinous Xanthomatosis","volume":"43","author":"Pilo","year":"2011","journal-title":"Muscle Nerve."},{"key":"B25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.yebeh.2012.04.121","article-title":"Early-onset epilepsy as the main neurological manifestation of Cerebrotendinous Xanthomatosis","volume":"24","author":"Pedroso","year":"2012","journal-title":"Epilepsy Behav."},{"key":"B26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mdc3.13188","article-title":"Cardiac involvement in movement disorders","volume":"8","author":"Rossi","year":"2021","journal-title":"Mov Disord Clin Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/brain\/122.8.1589","article-title":"Spinal xanthomatosis: a variant of Cerebrotendinous Xanthomatosis","volume":"122","author":"Verrips","year":"1999","journal-title":"Brain"},{"key":"B28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10545-014-9745-0","article-title":"Look carefully to the heels! a potentially treatable cause of spastic paraplegia","volume":"38","author":"Saute","year":"2015","journal-title":"J Inherit Metab Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2017.10.010","article-title":"Clinical and molecular characterization of hereditary spastic paraplegias: a next-generation sequencing panel approach","volume":"383","author":"Burguez","year":"2017","journal-title":"J Neurol Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"100719","DOI":"10.1016\/j.ymgmr.2021.100719","article-title":"Spinal Cerebrotendinous Xanthomatosis: a case report and literature review","volume":"26","author":"Atallah","year":"2021","journal-title":"Mol Genet Metab Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10072-019-04169-8","article-title":"The safety and effectiveness of chenodeoxycholic acid treatment in patients with Cerebrotendinous Xanthomatosis: two retrospective cohort studies","volume":"41","author":"Verrips","year":"2020","journal-title":"Neurol Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0002-9394(14)72206-8","article-title":"Ocular and systemic manifestations of Cerebrotendinous Xanthomatosis","volume":"120","author":"Cruysberg","year":"1995","journal-title":"Am J Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0002-9394(14)76874-6","article-title":"Juvenile cataract associated with chronic diarrhea in pediatric Cerebrotendinous Xanthomatosis","volume":"112","author":"Cruysberg","year":"1991","journal-title":"Am J Ophthalmol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1542\/peds.2008-0192","article-title":"Chronic diarrhea and juvenile cataracts: think Cerebrotendinous Xanthomatosis and treat","volume":"123","author":"Berginer","year":"2009","journal-title":"Pediatrics."},{"key":"B35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-016-0419-x","article-title":"Natural history of Cerebrotendinous Xanthomatosis: a paediatric disease diagnosed in adulthood","volume":"11","author":"Degos","year":"2016","journal-title":"Orphanet J Rare Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1038\/tp.2013.76","article-title":"Psychiatric manifestations in Cerebrotendinous Xanthomatosis","volume":"3","author":"Fraidakis","year":"2013","journal-title":"Transl Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10545-013-9674-3","article-title":"A suspicion index for early diagnosis and treatment of Cerebrotendinous Xanthomatosis","volume":"37","author":"Mignarri","year":"2014","journal-title":"J Inherit Metab Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e637","DOI":"10.1212\/WNL.0000000000004967","article-title":"Teaching neuroimages: Cerebrotendinous Xanthomatosis: a rare treatable adult-onset lipid storage disease","volume":"90","author":"Makary","year":"2018","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s11011-021-00714-7","article-title":"Patients with Cerebrotendinous Xanthomatosis diagnosed with diverse multisystem involvement","volume":"36","author":"Kisa","year":"2021","journal-title":"Metab Brain Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e24687","DOI":"10.1097\/MD.0000000000024687","article-title":"The clinical and imaging features of Cerebrotendinous Xanthomatosis: a case report and review of the literature","volume":"100","author":"Ma","year":"2021","journal-title":"Medicine."},{"key":"B41","doi-asserted-by":"publisher","first-page":"S387","DOI":"10.1007\/s10545-008-0963-1","article-title":"Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX","volume":"31","author":"Sain-van der Velden","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"56ra81","DOI":"10.1126\/scitranslmed.3001417","article-title":"Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease","volume":"2","author":"Porter","year":"2010","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1515\/jpem-2019-0314","article-title":"A novel etiologic factor of highly elevated cholestanol levels: progressive familial intrahepatic cholestasis","volume":"33","author":"Yavas","year":"2020","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/jimd.12219","article-title":"Misdiagnosis of CTX due to propofol: the interference of total intravenous propofol anesthesia with bile acid profiling","volume":"43","author":"Claesen","year":"2020","journal-title":"J Inherit Metab Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12944-019-1176-3","article-title":"Age-related changes of cholestanol and lathosterol plasma concentrations: an explorative study","volume":"18","author":"Gelzo","year":"2019","journal-title":"Lipids Health Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jns.2005.10.019","article-title":"Could steroids mask the diagnosis of Cerebrotendinous Xanthomatosis?","volume":"243","author":"Siman-Tov","year":"2006","journal-title":"J Neurol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s00415-019-09650-0","article-title":"Levels of 7alpha-hydroxycholesterol and\/or 7alpha-hydroxy-4-cholest-3-one are the optimal biochemical markers for the evaluation of treatment of cerebrotendinous Xanthomatosis","volume":"267","author":"L\u00fctjohann","year":"2020","journal-title":"J Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3389\/fendo.2018.00309","article-title":"Sterol 27-hydroxylase polymorphism significantly associates with shorter telomere, higher cardiovascular and type-2 diabetes risk in obese subjects","volume":"9","author":"Pavanello","year":"2018","journal-title":"Front Endocrinol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"758210","DOI":"10.3389\/fphar.2021.758210","article-title":"Pharmacy compounded medicines for patients with rare diseases: lessons learned from chenodeoxycholic acid and cholic acid","volume":"12","author":"Polak","year":"2021","journal-title":"Front Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/archneur.59.4.527","article-title":"Cerebrotendinous Xanthomatosis: a rare disease with diverse manifestations","volume":"59","author":"Moghadasian","year":"2002","journal-title":"Arch Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1194\/jlr.P048603","article-title":"On the formation of 7-ketocholesterol from 7-dehydrocholesterol in patients with CTX and SLO","volume":"55","author":"Bj\u00f6rkhem","year":"2014","journal-title":"J Lipid Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.410180418","article-title":"Treatment of Cerebrotendinous Xanthomatosis with chenodeoxycholic acid","volume":"18","author":"Pedley","year":"1985","journal-title":"Ann Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10048-022-00688-3","article-title":"Inherited metabolic diseases mimicking hereditary spastic paraplegia (HSP): a chance for treatment","volume":"23","author":"Teive","year":"2022","journal-title":"Neurogenetics."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1194\/jlr.M087999","article-title":"Newborn screening for Cerebrotendinous Xanthomatosis is the solution for early identification and treatment","volume":"59","author":"DeBarber","year":"2018","journal-title":"J Lipid Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41436-020-0846-x","article-title":"Toward newborn screening of Cerebrotendinous Xanthomatosis: results of a biomarker research study using 32,000 newborn dried blood spots","volume":"22","author":"Hong","year":"2020","journal-title":"Genet Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1194\/jlr.P075051","article-title":"A newborn screening method for Cerebrotendinous Xanthomatosis using bile alcohol glucuronides and metabolite ratios","volume":"58","author":"Vaz","year":"2017","journal-title":"J Lipid Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e968","DOI":"10.1212\/WNL.0000000000012154","article-title":"Teaching neuroimage: symmetric deep cerebellar white matter T2 and susceptibility-weighted imaging hypointense lesions in a case of Cerebrotendinous Xanthomatosis","volume":"97","author":"Zhang","year":"2021","journal-title":"Neurology."},{"key":"B58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.parkreldis.2011.06.004","article-title":"Parkinsonism as neurological presentation of late-onset Cerebrotendinous Xanthomatosis","volume":"18","author":"Mignarri","year":"2012","journal-title":"Parkinsonism Relat Disord."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/mds.25229","article-title":"Atypical parkinsonism and Cerebrotendinous Xanthomatosis: report of a family with corticobasal syndrome and a literature review","volume":"27","author":"Rubio-Agusti","year":"2012","journal-title":"Mov Disord."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00415-019-09377-y","article-title":"Cholic acid as a treatment for Cerebrotendinous Xanthomatosis in adults","volume":"266","author":"Mandia","year":"2019","journal-title":"J Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10545-018-0162-7","article-title":"Treatment with chenodeoxycholic acid in Cerebrotendinous Xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes","volume":"41","author":"Amador","year":"2018","journal-title":"J Inherit Metab Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1006\/bbrc.1998.9497","article-title":"Cholestanol induces apoptosis of cerebellar neuronal cells","volume":"256","author":"Inoue","year":"1999","journal-title":"Biochem Biophys Res Commun."},{"key":"B63","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.neulet.2011.11.036","article-title":"The bile steroid chenodeoxycholate is a potent antagonist at NMDA and GABA(A) receptors","volume":"506","author":"Schubring","year":"2012","journal-title":"Neurosci Lett."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacl.2018.06.008","article-title":"Diagnosis, treatment, and clinical outcomes in 43 cases with Cerebrotendinous Xanthomatosis","volume":"12","author":"Duell","year":"2018","journal-title":"J Clin Lipidol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/WNL.0000000000201112","article-title":"Long-term MRI findings in patients with Cerebrotendinous Xanthomatosis treated with chenodeoxycholic acid","volume":"99","author":"Stelten","year":"2022","journal-title":"Neurology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00431-015-2584-7","article-title":"Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with Cerebrotendinous Xanthomatosis: implications for treatment","volume":"175","author":"Huidekoper","year":"2016","journal-title":"Eur J Pediatr."},{"key":"B67","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/WNF.0b013e318288076a","article-title":"Neurological outcome in Cerebrotendinous Xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis","volume":"36","author":"Yahalom","year":"2013","journal-title":"Clin Neuropharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-004-0221-x","article-title":"Spinal phenotype of Cerebrotendinous Xanthomatosis \u2013 a pitfall in the diagnosis of multiple sclerosis","volume":"251","author":"Bartholdi","year":"2004","journal-title":"J Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0022-510X(94)90237-2","article-title":"Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use","volume":"125","author":"Kuriyama","year":"1994","journal-title":"J Neurol Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0026-0495(99)90040-9","article-title":"Effect of simvastatin in addition to chenodeoxycholic acid in patients with Cerebrotendinous Xanthomatosis","volume":"48","author":"Verrips","year":"1999","journal-title":"Metabolism."},{"key":"B71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clineuro.2013.12.008","article-title":"Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of Cerebrotendinous Xanthomatosis: a case report","volume":"118","author":"Luyckx","year":"2014","journal-title":"Clin Neurol Neurosurg."},{"key":"B72","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jns.2003.07.005","article-title":"Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for Cerebrotendinous Xanthomatosis","volume":"216","author":"Ito","year":"2003","journal-title":"J Neurol Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10072-004-0320-6","article-title":"Normalisation of serum cholestanol concentration in a patient with Cerebrotendinous Xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis","volume":"25","author":"Dotti","year":"2004","journal-title":"Neurol Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s10545-008-0815-z","article-title":"Prospective treatment of Cerebrotendinous Xanthomatosis with cholic acid therapy","volume":"31","author":"Pierre","year":"2008","journal-title":"J Inherit Metab Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0009-8981(85)90182-2","article-title":"Bile acid therapies applied to patients suffering from Cerebrotendinous Xanthomatosis","volume":"152","author":"Koopman","year":"1985","journal-title":"Clin Chim Acta."},{"key":"B76","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.metabol.2003.12.003","article-title":"Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of Cerebrotendinous Xanthomatosis","volume":"53","author":"Batta","year":"2004","journal-title":"Metabolism."},{"key":"B77","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.omtm.2021.07.002","article-title":"Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of Cerebrotendinous Xanthomatosis","volume":"22","author":"Lumbreras","year":"2021","journal-title":"Mol Ther Methods Clin Dev."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1049850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T01:37:18Z","timestamp":1671759438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1049850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":77,"alternative-id":["10.3389\/fneur.2022.1049850"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1049850","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"article-number":"1049850"}}